Chronic Lymphocytic Leukemia

Yannis K. Valtis, MD, provides background on a single-institution, retrospective cohort study which assessed laboratory and clinical tumor lysis syndrome in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

An expert on CLL/SLL provides clinical insights on approaching the treatment of patients who progress beyond initial therapy.

Mazyar Shadman, MD, MPH, discusses the safety profile of BTK inhibitors in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

The combination of acalabrutinib and venetoclax with or without obinutuzumab improved survival vs standard chemotherapy in patients with previously untreated chronic lymphocytic leukemia.

Following recent updates from the SEQUOIA Arm D and CAPTIVATE studies, Mazyar Shadman, MD, MPH, discusses the future implications of fixed-duration therapy for patients with CLL/SLL.

An expert on hematologic malignancies discusses the ongoing CAPTIVATE trial evaluating ibrutinib plus venetoclax in patients with treatment-naïve CLL/SLL.

A blood cancer specialist discusses the latest data from the SEQUOIA Arm D trial investigating zanubrutinib plus venetoclax in treatment-naïve patients with CLL and del(17p) and/or TP53 mutations.

Mazyar Shadman, MD, MPH, describes his clinical approach to treating patients with high-risk CLL/SLL, including those with or without del(17p) or TP53 mutations.

Mark Geyer, MD, and Yannis K. Valtis, MD, discussed real-world findings on the incidence, prevention, and management of tumor lysis syndrome in patients with CLL treated with venetoclax.

Mark Geyer, MD, and Yannis K. Valtis, MD, delved into the background and findings from a study looking at clinical and laboratory tumor lysis syndrome in patients with CLL who were treated with venetoclax in the inpatient and outpatient settings.

Acalabrutinib and zanubrutinib showed longer median TTD and TTNT compared to ibrutinib in CLL/SLL patients. Cardiovascular adverse effects were less frequent with acalabrutinib and zanubrutinib than with ibrutinib.

An increased likelihood of response was also observed in patients who received no more than 3 lines of therapy prior to liso-cel in the TRANSCEND CLL 004 trial.

Zanubrutinib plus venetoclax achieved a 100% overall response rate in patients with treatment-naive CLL/SLL harboring 17p deletions and/or TP53 mutations.

During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed subgroup analyses and adverse events from the ALPINE trial of zanubrutinib for a patient with relapsed/refractory chronic lymphocytic leukemia in the second article of a 2-part series.

During a Case-Based Roundtable® event, Nakhle Saba, MD, discussed the role of Bruton tyrosine kinase inhibitors for patients with relapsed or refractory chronic lymphocytic leukemia, especially in patients with a poor health history.

In an interview with Targeted Oncology, Paolo Ghia, MD, PhD, discussed the 5-year results from the CAPTIVATE study in chronic lymphocytic leukemia and/or small lymphocytic lymphoma.

During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.

Findings from a real-world study identified that venetoclax was a safe treatment option and did not lead to higher rates of death for patients with chronic lymphocytic leukemia who were diagnosed with COVID-19.

During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events on patients who receive a Bruton tyrosine kinase inhibitor for chronic lymphocytic leukemia.

A 2-year follow-up study showed that ibrutinib maintained efficacy and safety among patients with chronic lymphocytic leukemia, highlighting its importance in the field. 

During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.

In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.

Treatment with venetoclax appeared to improve responses in patients with relapsed or refractory chronic lymphocytic leukemia, according to findings from a phase 3b study.

In the first article of a 2-part series, Marc S. Hoffmann, MD, looks at the factors to take into consideration before initiating another line of treatment in patients with chronic lymphocytic leukemia.

Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Mazyar Shadman, MD, MPH, to discuss the ALPINE study looking at zanubrutinib vs ibrutinib in relapsed or refractory CLL.